Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus on the top line, with revenue of $13.8M vs. $11.6M expected, driven by a 24% YoY increase in manufacture and supply revenue. While GAAP EPS of -$0.18 missed the -$0.10 mean estimate due to a $11.7M one-time debt extinguishment loss, adjusted net loss (excluding that item) was $11.2M, beating the $12.6M expected normalized loss. Management reaffirmed FY2026 revenue guidance of $46M-$50M and remains on track for the critical Anaphylm™ NDA resubmission in Q3 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Aquestive Therapeutic(AQST) the Revenue is 13.82 M (+38.15%), Beat estimate;the EBIT is -8.223 M (+27.67%), Beat estimate;the EPS is -0.18 (-28.57%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B38.15%
0.01B15.57%
+0.00B22.58%
EBITExceed expectations
-0.01B27.67%
-0.01B15.24%
+0.00B12.43%
EPSMiss expectations
-0.1828.57%
-0.104325.51%
-0.075754.08%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf